Biased Ligands. Better Drugs.

Trevena to Host Analyst Day on July 20, 2017
7/12/17

KING OF PRUSSIA, Pa., July 12, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host an Analyst Day on Thursday, July 20, 2017, in New York City. Presentations will begin at 12:00 p.m. EDT and will be simultaneously webcast. The event is expected to conclude by 3:00 p.m.

The presentations will focus on the Company’s clinical portfolio and will feature members of the Trevena management team and leading external experts in acute pain management in the hospital, including:

  • Eugene R. Viscusi, M.D. Chief of Pain Medicine, Director of Acute Pain Management, Sidney Kimmel Medical College, Thomas Jefferson University; President-Elect, The American Society of Regional Anesthesia and Pain Medicine,
  • Peter Whang, M.D., FACS. Associate Professor, Department of Orthopaedics & Rehabilitation, Yale University School of Medicine,
  • Michael H. Bourne, M.D. Orthopaedic Surgeon, Salt Lake Orthopaedic Clinic; Chairman, Division of Orthopaedic Surgery, St. Mark’s Hospital; ATHENA investigator, and
  • Hadi Najafian, D.O., FACS, FASCRS. Colon & Rectal Surgeon, West Valley Colon & Rectal Surgery Center.

To join the live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.

About Trevena 

Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company’s lead program is OLINVO™ (oliceridine injection), which has completed two successful Phase 3 trials for the management of moderate-to-severe acute pain. Trevena has discovered four novel and differentiated drug candidates, including OLINVO. Trevena also has discovered TRV250, in early clinical development for the treatment of acute migraine. The Company maintains an early stage portfolio of drug discovery programs.

Contacts

Trevena, Inc.

Investors:
Jonathan Violin, Ph.D.
Vice President, Corporate Strategy & Investor Relations
610-354-8840 x231
jviolin@trevena.com

or

Media:
Public Relations
PR@trevena.com

Copyright © Trevena, Inc.